Trial Profile
A Retrospective study to evaluate the efficacy of Rituximab-Bendamustine-Bortezomib-Dexametasone (RiBVD regimen) in patients with Mantle cell lymphoma irrespective of the prior treatments
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2017
Price :
$35
*
At a glance
- Drugs Bendamustine (Primary) ; Bortezomib (Primary) ; Dexamethasone (Primary) ; Rituximab (Primary)
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- 14 Jan 2017 New trial record
- 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology